Search PubMed⌕ Search

Biomedical subjects

M Samson

Publications and source records attributed to M Samson.

At least 127 records · Page 7Linked to original sources
PubMed1976

Phase I study of oral mitomycin C.

This study demonstrates that the gastrointestinal absorption of oral mitomycin C is variable and that myelosuppression correlates most closely with the peak serum concentration. The probable maximal-tolerated dose of oral mitomycin C is 45-50 mg/m2.

Administration, Oral↗
PubMed1976

Hepatic artery infusion of 5-FUDR after prior systemic 5-fluorouracil.

Twenty-one patients with disseminated colon carcinoma and clinically significant liver metastases were treated with 5-FUDR via hepatic artery infusion (HAI). All patients had previously received systemic chemotherapy consisting of either 5-fluorouracil aone or in combination with other agents. At the time of the initiation of the HAI, clinical disease in all patients was progressing. A PR of hepatic metastases was noted in eight patients (35%) with a median and mean duration of response of 4.5 and 5.0 months respectively. The median and mean survival from the start of HAI for responders was 8.0 and 9.0 months and for nonresponders was 1.0 and 1.6 months respectively. It appears that a significant response rate can be achieved with HAI of 5-FUDR in spite of previous exposure to fluorinated pyrimidines.

Adult↗
PubMed1975

A phase II study of methyl CCNU in the treatment of solid tumors and lymphomas: a Southwest Oncology Group study.

In March of 1972, the Southwest Oncology Group initiated a Phase II study, No. 7200, utilizing methyl-CCNU in the treatment of patients with solid tumors and lymphomas. Initially, they received 200 mg/m2 orally as a single dose every 6 weeks. The dose was subsequently reduced in poor-risk patients to 150 mg/m2. There were 69 responses noted in 675 evaluable patients (10%). The highest response rates were noted in patients with Hodgkin's disease (13/31, 35%), malignant gliomas of the brain (8/29, 28%), anaplastic carcinomas of the lung (5/20, 25%), and squamous cell carcinomas of the head and neck (5/29, 17%). Squamous cell tumors appeared to be more responsive than adenocarcinomas (15% vs. 5%, respectively). Hematologic toxicity was cumulative, and was influenced by dose and prior treatment. There appeared to be no cross-resistance in patients previously treated with alkylating agents. Methyl-CCNU is an active antineoplastic agent. Further studies are indicated in order to determine relative effectiveness.

Adenocarcinoma↗
PubMed1975

[Trial of use of computer technology for the assistance of neurologic diagnosis].

This article describes our experience of computer-assisted diagnosis. The original aspects of this work are both the subject chosen and the method used. Our study of clinical and semiological data included the whole of neurological signs above the spinal cord. The interest of the method, based on Bayes theory was in the use of auto-learning and the sample of patients studied as our experience increased. The preliminary results are encouraging, with 85 % correct results, if one considers the first three replies.

Bayes Theorem↗